Company
Pharmobedient
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
22
0 still marketed
Novel approvals
3
Approvals since 2021
1
Originals and new uses
Phase 3 trials
0
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Abacavir Sulfate and Lamivudine approved Dec 22, 2023
- Impeklo approved May 19, 2020
- Aerospan Hfa new use Aug 28, 2013
- Zidovudine approved Feb 23, 2011
- Aerospan Hfa approved Jan 27, 2006
- Mentax-Tc approved Oct 17, 2002
- Mentax new use Jun 6, 2001
- Accuneb approved Apr 30, 2001
- Duoneb approved Mar 21, 2001
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
No recruiting Phase 3 trials under this sponsor name.
Marketed drugs (0)
Newest FDA action first.
None still marketed under these names.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.